



## **IMAGIA CANEXIA HEALTH ANNOUNCES THREE ABSTRACTS TO BE PRESENTED AT AACR ANNUAL MEETING 2023 HIGHLIGHTING THE COMPANY'S LATEST RESEARCH FINDINGS**

MONTREAL, CANADA, March 28, 2023 – Imagia Canexia Health announced today that three abstracts highlighting the company's new learnings and tools will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14–19, 2023, at the Orange County Convention Center in Orlando, Florida.

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

"Our ability to accelerate access to precision care by combining AI expertise with advanced molecular biopsy solutions provides our hospital and lab partners with actionable insights to deliver cost-effective cancer testing to patients no matter where they seek treatment." –Vincent Funari, Chief Scientific Officer

The abstracts accepted for presentation at AACR 2023 will highlight new learnings and tools that demonstrate our ongoing commitment to close the health equity gap in cancer. Stop by our booth #366 and attend one of our poster sessions:

### **Abstract presentations**

#### **Development of a one-step molecular classifier for endometrial carcinoma using an amplicon-based gene panel and next generation sequencing technology**

Date / Time: Tuesday April 18, 9:00 AM – 12:30 PM ET

Location: Section 44

Poster number: 21

Presenter: Melissa McConechy, Principal Scientist

ProMisE provides valuable prognostic and predictive information to direct care, however, multiple molecular results are often received from different time periods and/or from different centers which can cause delays. Therefore, we developed a classifier that relies on a single DNA-based NGS test with the goal of recapitulating the prognostic value of ProMisE by producing concordant results.



## **Method for identifying microsatellite instability high DNA abnormality samples**

Date / Time: Tuesday April 18, 9:00 AM – 12:30 PM ET

Location: Section 32

Poster number: 10

Presenter: Rosalia Aguirre–Hernandez, Computational Biology Senior Manager

Sequencing costs can add up quickly for tissue biopsies. We developed a Machine Learning method for classifying a tissue sample as being microsatellite instability high (MSI-H) without using normal tissue from the same person, saving costs for the patient.

## **Liquid biopsy testing in metastatic or advanced breast cancer patients during the COVID–19 pandemic**

Date / Time: Tuesday April 18, 1:30 PM – 5:00 PM ET

Location: Section 41

Poster number: 14

Presenter: Benjamin Furman, Senior Bioinformatician

For Project ACTT, a population of Canadian women with metastatic breast cancer were tested using a liquid biopsy gene panel during the COVID–19 pandemic to identify biomarkers that could match them with targeted therapies. We will present the results of this study on earlier use of targeted therapies, improving outcomes through liquid biopsy.

### **About Imagia Canexia Health**

Imagia Canexia Health (ICH) is a genomics–based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions. Leveraging AI–based informatics for treatment selection and monitoring, oncologists now have leading clinical decision support right at their fingertips. With a network of over 20 hospitals and reference labs worldwide, ICH ensures that doctors have the right insights to deliver cost–effective cancer testing to patients no matter where they seek treatment. Join ICH in closing the health–equity gap in cancer: [imagiacanexiahealth.com](http://imagiacanexiahealth.com)

### **Contact:**

Shelley Epstein, Executive Vice–President, Corporate and Public Affairs

Imagia Canexia Health

514–451–6343